Council of Scientific and Industrial Research

Nicholas Piramal India Limited

Anil Kumar Dwivedi

Satyawan Singh

Girish Kumar Jain

Sudhir Srivastava

Varsha Gupta

Anil Kumar

Ram Pratap

Naibedya Chattopadhyay

Sunil Kumar Puri

Ritu Trivedi

Ram Chandra Gupta

Omkar Prasad Asthana

Vishal Singh

Prem Prakash

Jagdishwar Sahai Srivastava

Dinesh Kumar Dikshit

Shio Kumar Singh

Vikash Chandra Pandey

Sushil Kumar

Suman Preet Singh Khanuja

Amit Kumar

Dharam Chand Jain

Swati Ajay Piramal

Rajender Singh Sangwan

Man Mohan Singh

Neelam Singh Sangwan

Madhu Dikshit

Atul Goel

Wahajul Haq

Prabhat Ranjan Mishra

Ram Raghubir

Srikanta Kumar Rath

Avinash Kumar

Divya Singh

Guru Prakash Dutta

Sudhanshu Saxena

Onkar Prasad Asthana

Jiaur Rahaman Gayen

Pratima Srivastava

Guru Prasad Dutta

Harsh Pati Thapliyal

Amiya Prasad Bhaduri

Tanveer Irshad Siddiqui

Rabi Sankar Bhatta

Manoj Kumar Barthwal

Ankita Misra

Vivek Khanna

Manish Jain

Lakshmi Manickavasagam

Sumit Chaurasia

Francis Joseph Pinto

Nuzhat Kamal

Aseem Umesh

Sangeeta Dhawan

Renu Tripathi

Ranjendra Singh Bhakuni

Jagdishwar Sahay Srivastava

Abnish Kumar Gautam

Rashmi Pandey

Madhu Khanna

Puvvada Sri Ramchandra Murthy

Girish Kumar Gupta

Kamini Srivastava

Rakesh Shukla

Himanshu Singh

Hafsa Ahmad

Vivek Vidyadhar Bhosale

Suresh Pratap Singh Gaur

Smrati Bhaduaria

Kiran Khandelwal

Sarika

Amar Bahadur Singh

Mukesh Srivastava

Alok Kumar Verma

Sharad Sharma

Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2S)-1-(4-methylphenylmethyl)-5-oxo-(3S)-{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p-methylphenylmethyl)1pyroglutamate in good chiral purity. 

Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl)-pyrrolidine as inhibitors of collagen induced platelet activation and adhesion

Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion The present invention provides chiral (2S)-1-(4-methyl-phenylmethyl)-5-oxo-(3S)&#x2014;{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)&#x2014;{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p methylphenylmethyl)lpyroglutamate in good chiral purity. 

Chiral 1-(4-methylphenylmethyl)-5-OXO-{N-[3-T-butoxycarbonyl-aminomethyl)]-piperidin-1-yl-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion

The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R, R, R, R, R, R, R, Rare independently selected from the groups consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted aroyl, optionally substituted acyloxy, optionally substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro but not limited to this; wherein RRor RRor RRmay be connected and form either a five membered ring or a six membered ring such as optionally substituted furan, optionally substituted dihydrofuran, optionally substituted pyran; or may be connected through a methylenedeoxy moiety; wherein X is selected from the units consisting of optionally a ketone group, optionally a methylene group, optionally substituted methylene group, optionally substituted alkene; wherein Y and Z is selected from the units consisting of CH, C&#x2014;OH, C-Me, C&#x2014;OMe with the proviso that bond between Y and Z is a single bond; Wherein Y and Z may be a carbon atom with the proviso that bond between Y and Z is a double bond. The compounds of the general formula is useful for the prevention and treatment of bone related disorders. 

Substituted benzfurochromenes and related compounds for the prevention and treatment of bone related disorders

The present invention relates to a microcapsule for controlled release of flavanoid compound and a process for preparation thereof. The microcapsule comprising a core particle consisting of a calcium salt, Pluronic F68 [poly (ethylene oxide-co-polypropylene oxide), block poly oxyethylene-polypropylene block copolymer], loaded with a flavanoid compound, the resulting core particle having a plurality of alternate layers of cationic and anionic polyelectrolytes adsorbed thereon and an outer layer formed by a bile salt, wherein the flavanoid is ranging between 10 to 96% by weight.

Controlled release micro-capsule for osteogenic action

A combination kit for the treatment of malaria caused by() having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.

Combination kit used in the treatment of malaria

The present invention a novel use of primaquine derivative N-(3-ethylidinotetrahydrofuran-2-one)-N-(6-methoxy-8-quinolinyl)-1,4-pentanediamine in the treatment and controlling the spread of malaria. In particular, the present invention discloses a method of treatment of malaria by the use of primaquine derivative N-(3-ethylidinotetrahydrofuran-2-one)-N-(6-methoxy-8-quinolinyl)-1,4-pentanediamine as a gametocytocidal agent.

[object Object]

The invention provides novel inclusion complexes of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin, pharmaceutical preparations containing these inclusion complexes of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivatives, the complexes being better soluble in water and having improved biopharmaceutical properties such as lesser toxicity, better analgesic action and non-addiction properties.

Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment

The present invention relates to a synergistic formulation comprising pharmaceutically effective amount of &agr;/&bgr; arteether and a neutralized refined vegetable oil suitable for administration by rectal route, method for the treatment of cerebral and comatose malaria and process for the preparation of the said formulation.

Synergistic anti-malarial formulation

Growing community of inventors

Lucknow, India

Anil Kumar Dwivedi